Association between the polymorphisms of urokinase plasminogen activation system and cancer risk: a meta-analysis

References

• AndreasenPAKjollerLChristensenLDuffyMJThe urokinase-type plasminogen activator system in cancer metastasis: a reviewInt J Cancer19977211229212216
   PubMed Web of Science ®Google Scholar
• BergerDHPlasmin/plasminogen system in colorectal cancerWorld J Surg200226776777111965442
   PubMed Web of Science ®Google Scholar
• DuffyMJThe urokinase plasminogen activator system: role in malignancyCurr Pharm Des2004101394914754404
   PubMed Web of Science ®Google Scholar
• SideniusNBlasiFThe urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapyCancer Metastasis Rev2003222–320522212784997
   PubMed Web of Science ®Google Scholar
• GondiCSRaoJSTherapeutic potential of siRNA-mediated targeting of urokinase plasminogen activator, its receptor, and matrix metallopro-teinasesMethods Mol Biol200948726728119301652
   PubMedGoogle Scholar
• YangSFHsiehYSLueKHChuSCChangICLuKHEffects of nonsteroidal anti-inflammatory drugs on the expression of urokinase plasminogen activator and inhibitor and gelatinases in the early osteoarthritic knee of humansClin Biochem2008411–210911617996201
   PubMed Web of Science ®Google Scholar
• YangSFWangPHLinLYA significant elevation of plasma level of matrix metalloproteinase-9 in patients with high-grade intraepithelial neoplasia and early squamous cell carcinoma of the uterine cervixReprod Sci200714771071818000233
   PubMed Web of Science ®Google Scholar
• DuffyMJMaguireTMMcDermottEWO’HigginsNUrokinase plasminogen activator: a prognostic marker in multiple types of cancerJ Surg Oncol199971213013510389872
   PubMed Web of Science ®Google Scholar
• SakakibaraTHibiKKoikeMPlasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancerBr J Cancer200593779980316091756
   PubMed Web of Science ®Google Scholar
• YangJLSeetooDWangYUrokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targetsInt J Cancer200089543143911008205
   PubMed Web of Science ®Google Scholar
• HildenbrandRAllgayerHMarxAStroebelPModulators of the urokinase-type plasminogen activation system for cancerExpert Opin Investig Drugs2010195641652
   PubMed Web of Science ®Google Scholar
• KwaanHCMcMahonBThe role of plasminogen-plasmin system in cancerCancer Treat Res2009148436619377918
   PubMedGoogle Scholar
• PepperMSRole of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesisArterioscler Thromb Vasc Biol20012171104111711451738
   PubMed Web of Science ®Google Scholar
• SuCKYehKTYehCBGenetic polymorphism of the plasminogen activator inhibitor-1 is associated with an increased risk of endometrial cancerJ Surg Oncol2011104775575921761413
   PubMed Web of Science ®Google Scholar
• CastelloREspanaFVazquezCPlasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severityThromb Res2006117548749215907980
   PubMed Web of Science ®Google Scholar
• JorgensonEDeitcherSRCicekMPlasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family historyProstate200767217217717044080
   PubMed Web of Science ®Google Scholar
• ShihCMKuoWHLinCWAssociation of polymorphisms in the genes of the urokinase plasminogen activation system with susceptibility to and severity of non-small cell lung cancerClin Chim Acta20114121–219419820937265
   PubMed Web of Science ®Google Scholar
• WengCJLinCWChungTTTsaiCMChenMKYangSFImpact of uPA system gene polymorphisms on the susceptibility of environmental factors to carcinogenesis and the development of clinicopathology of oral cancerAnn Surg Oncol201118380581221125336
   PubMed Web of Science ®Google Scholar
• WengCJTsaiCMChenYCEvaluation of the association of urokinase plasminogen activator system gene polymorphisms with susceptibility and pathological development of hepatocellular carcinomaAnn Surg Oncol201017123394340120706793
   PubMed Web of Science ®Google Scholar
• WuCYWuMSChenYJClinicopathological significance of urokinase-type plasminogen activator genotypes in gastric cancerHepatogastroenterology20085586–871890189419102416
   PubMedGoogle Scholar
• WangSCaoQWangXPAI-1 4G/5G polymorphism contributes to cancer susceptibility: evidence from meta-analysisPLoS One201382e5679723437240
   PubMed Web of Science ®Google Scholar
• CamargoMCMeraRCorreaPInterleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms and gastric cancer: a meta-analysisCancer Epidemiol Biomarkers Prev20061591674168716985030
   PubMed Web of Science ®Google Scholar
• GaoLBPanXMLiLJRAD51 135G/C polymorphism and breast cancer risk: a meta-analysis from 21 studiesBreast Cancer Res Treat2011125382783520640595
   PubMed Web of Science ®Google Scholar
• HigginsJPThompsonSGDeeksJJAltmanDGMeasuring inconsistency in meta-analysesBMJ2003327741455756012958120
   PubMed Web of Science ®Google Scholar
• PetittiDBMeta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis: Methods for Quantitative Synthesis in MedicineOxford University PressOxford1999
   Google Scholar
• BeggCBMazumdarMOperating characteristics of a rank correlation test for publication biasBiometrics1994504108811017786990
   PubMed Web of Science ®Google Scholar
• EggerMDaveySGSchneiderMMinderCBias in meta-analysis detected by a simple, graphical testBMJ199731571096296349310563
   PubMed Web of Science ®Google Scholar
• BentovYBrownTJAkbariMRPolymorphic variation of genes in the fibrinolytic system and the risk of ovarian cancerPLoS One200946e591819526059
   PubMed Web of Science ®Google Scholar
• ForstiALeiHTavelinBPolymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancerAnn Oncol200718121990199417804466
   PubMed Web of Science ®Google Scholar
• LeiHHemminkiKJohanssonRPAI-1-675 4G/5G polymorphism as a prognostic biomarker in breast cancerBreast Cancer Res Treat2008109116517517616807
   PubMed Web of Science ®Google Scholar
• MittalRDSrivastavaDSMishraDKIs urokinase gene 3′-UTR polymorphism associated with prostate cancer?Cancer Biomark20051628729217192053
   PubMedGoogle Scholar
• PrzybylowskaKSmolarczykKBlasiakJA C/T polymorphism in the urokinase-type plasminogen activator gene in colorectal cancerJ Exp Clin Cancer Res200120456957211876553
   PubMed Web of Science ®Google Scholar
• TeeYTWangPHTsaiHTGenetic polymorphism of urokinase-type plasminogen activator is interacting with plasminogen activator inhibitor-1 to raise risk of cervical neoplasiaJ Surg Oncol2012106220420822354580
   PubMed Web of Science ®Google Scholar
• TsaiMHChenWCChenHYTsaiFJUrokinase gene 3′-UTR T/C polymorphism is associated with oral cancerJ Clin Lab Anal200418527627915356878
   PubMed Web of Science ®Google Scholar
• TurkmenBSchmittMSchmalfeldtBMutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancerElectrophoresis19971856866899194591
   PubMed Web of Science ®Google Scholar
• Garza-GonzalezEBosques-PadillaFJMendoza-IbarraSIFlores-GutierrezJPMaldonado-GarzaHJPerez-PerezGIAssessment of the toll-like receptor 4 Asp299Gly, Thr399Ile and interleukin-8-251 polymorphisms in the risk for the development of distal gastric cancerBMC Cancer200777017462092
   PubMed Web of Science ®Google Scholar
• YoshimotoMUshiyamaYSakaiMCharacterization of single chain urokinase-type plasminogen activator with a novel amino-acid substitution in the kringle structureBiochim Biophys Acta19961293183898652631
   PubMed Web of Science ®Google Scholar
• AhmadAKongDWangZSarkarSHBanerjeeSSarkarFHDown-regulation of uPA and uPAR by 3,3′-diindolylmethane contributes to the inhibition of cell growth and migration of breast cancer cellsJ Cell Biochem2009108491692519693769
   PubMed Web of Science ®Google Scholar
• AlmasiCEHoyer-HansenGChristensenIJPappotHPrognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancerAPMIS20091171075576119775344
   PubMed Web of Science ®Google Scholar
• IllemannMBirdNMajeedATwo distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastasesInt J Cancer200912481860187019123477
   PubMed Web of Science ®Google Scholar
• KogianniGWalkerMMWaxmanJSturgeJEndo180 expression with cofunctional partners MT1-MMP and uPAR-uPA is correlated with prostate cancer progressionEur J Cancer200945468569319112015
   PubMed Web of Science ®Google Scholar
• ThomasCWiesnerCMelchiorSWUrokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancerBJU Int20091041293419154451
   PubMed Web of Science ®Google Scholar